The National Institute for Health and Care Excellence (NICE) faced "difficult decisions" when it deemed a breast cancer drug which can extend sufferers lives by "up to six months" was too expensive, according to a health expert.
Dr Hilary Jones told Daybreak the £90,000 price tag per patient would have meant taking funds away from other vital services the NHS provides.
More top news
Mostly cloudy with rain elsewhere.
A Labour government would bring contracts signed under the Private Finance Initiative back into the public sector, John McDonnell has said.